Orin
MTDNYSE·Medical - Diagnostics & Research

Mettler-Toledo International Inc. MTD

Market cap $30.5BP/E 34.1× trailingGross margin 58.4%Reports Thu 5 Nov, after the close
$1507.86
−11.29 (−0.74%)live 11:20 ET
52-wk $1023.05 – $1541.02
Watch
Orin's take
0.62conviction · moderate
Refreshed 17 Aug · take v6. A new filing or a print queues the next refresh.

Mettler-Toledo's Q2 2026 earnings beat and raised 2026 outlook signal a potential reacceleration led by China and emerging markets, but FY2025 fundamentals still show only 4.0% revenue growth, a net income growth of just 0.7%, and operating margin compression to 27.8% from 29.1% in FY2024 — not enough to justify the valuation premium of 31.8x trailing P/E (7% above peer median) and 6.9x P/S (46% above peer median). Insiders are net sellers over the trailing 24 months (-$23.5M net value), with the CFO and a director executing same-day option exercises and sales in early August 2026, and smart money positioning is only marginally positive at 0.0248 as of Q2 2026.

The stock trades above both its 50-day ($1,295) and 200-day ($1,321) moving averages, but MACD has turned bearish (histogram -4.72), suggesting near-term momentum may be fading after the post-earnings rally to $1,417.

What could go wrong

  • Margin compression persists. FY2025 operating margin declined to 27.8% from 29.1% in FY2024 despite revenue growth of 4.0%; if Q2 2026 reacceleration does not translate into sustained margin recovery, the premium multiple is unsupported.
  • Insider selling acceleration. Over the trailing 24 months, insiders net sold $23.5M in shares; in early August 2026 alone, the CFO and a director executed same-day option exercises and sold shares at prices above $1,430, signaling limited insider conviction at current levels.
  • Valuation stretch vs. peers. P/S of 6.9x is 46% above the peer median of 4.75x and EV/EBITDA of 23.7x is 26% above the peer median of 18.7x, leaving little room for disappointment if growth does not reaccelerate meaningfully.
  • Negative book equity and leverage. Total debt of $2.34B against negative stockholders' equity of -$23.6M as of FY2025 increases balance sheet fragility if end-market conditions deteriorate.

What would change my mind

Sustained margin recovery. Q3 2026 operating margin returns toward or above the FY2024 level of 29.1% with local-currency revenue growth above 6%bullish
Guidance cut or China deceleration. Company lowers 2026 sales or EPS outlook, or China/local-currency growth slows below 5% in Q3 2026bearish
Insider buying reversal. Insiders transition from net selling to open-market purchases exceeding $5M in aggregate over a quarterbullish
Technical breakdown. Stock closes below the 200-day moving average of $1,321 on sustained volumebearish

Where this comes from: derived_metrics FY2025 · derived_metrics FY2024 · peer_relative · insider summary. Orin's read on MTD; not advice.

Twelve months actual closes to 2026-09-24 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Vanguard Capital Management$1.7B0.0% of fund
Vanguard Portfolio Management$1.3B0.1% of fund
State Street$1.2B0.0% of fund
Alliancebernstein L.P$856.5M0.3% of fund
Geode Capital Management$780.5M0.0% of fund
Bank of New York Mellon$762.6M0.1% of fund

78 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 131 Form 4 filings, net −$24.8M. Of the 50 on hand, 0 were open-market purchases and 11 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about MTD

its filings · its transcripts · its numbers

Orin answers questions about MTD from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days →

Where it trades

vs its own 5y · Healthcare
MetricNowOwn medianSector
P/E34.1×33.6×26.4×
EV/EBITDA25.1×25.1×—
P/S7.43×7.14×—

Its P/E sits 60th percentile of its own last 5 years (−0.39σ from its own mean).

What the price assumes

15.8%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $0.8B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

19 firms · 2026-09-24
Consensus target

$1466

$1194 – $1600 · −3% against today's price

How they rate it
  • 8 buy or overweight
  • 11 hold
  • 0 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 33.8× of 6 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
MTDMettler-Toledo International Inc.$31B34.1×25.1×58.4%21.9%-1200%
AAgilent Technologies, Inc.$49B34.0×25.9×53.7%19.5%20%
DGXQuest Diagnostics Incorporated$26B24.8×15.9×33.1%9.2%14%
DXCMDexCom, Inc.$33B33.8×21.4×62.5%20.1%36%
IQVIQVIA Holdings Inc.$45B33.8×16.9×26.2%8.1%22%
STESTERIS plc$20B25.5×12.1×44.4%13.3%11%
WATWaters Corporation$42B107.0×52.4×50.8%3.6%2%

The median is of the 6 peers listed above and nothing else — check it against the column. This company trades 0.9% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 25.8×FY25 33.1×

What its sector has traded at

Healthcare
FY14 6.5×FY26 28.5×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$670$1130.18 · −41%2026-06-10
Levered DCF$633$1130.18 · −44%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $1507.86
52-week range$1023 – $1541
Analyst targets$1194 – $1600
Standard DCF$670 as of 2026-06-10, when it was $1130.18
Levered DCF$633 as of 2026-06-10, when it was $1130.18
At own 5y-median P/E (34×)$1496
At 5y P/E range (30–51×)$1340 – $2274
At sector P/E (26×)$1177

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.